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Rhesus macaque APOBEC3A (rhA3A) is capable of restricting both simian–human immunodeﬁciency
virus (SHIVΔvif) and human immunodeﬁciency virus (HIV-1Δvif) to a greater extent than hA3A. We
constructed chimeric A3A proteins to deﬁne the domains required for differential lentivirus restriction.
Substitution of amino acids 25–33 from rhA3A into hA3A was sufﬁcient to restrict HIVΔvif to levels
similar to rhA3A restriction of SHIVΔvif. We tested if differential lentivirus restriction is conserved
between A3A from Old World monkey and hominid lineages. A3A from African green monkey restricted
SHIVΔvif but not HIV-1Δvif and colobus monkey A3A restricted both wild type and SHIVΔvif and HIV-
1Δvif. In contrast, the gibbon ape A3A restricted neither SHIVΔvif nor HIV-1Δvif. Restriction of SHIVΔvif
and HIV-1Δvif by New World monkey A3A proteins was not conserved as the A3A from the squirrel
monkey but not the northern owl monkey restricted SHIVΔvif. Finally, the colobus A3A protein appears
to restrict by a novel post-entry mechanism.
& 2013 Published by Elsevier Inc.Introduction
The apolipoprotein B mRNA-editing, enzyme-catalytic,
polypeptide-like 3 (APOBEC3; A3) family of proteins in humans
have been shown to restrict the replication of many different
retroviruses (Sheehy et al., 2002; Chiu and Greene, 2009). In
humans and rhesus macaques, this family consists of seven
members (A3A, A3B, A3C, A3D, A3F, A3G and A3H) (Dang et al.,
2007; Hultquist et al., 2011; Jarmuz et al., 2002; Schmitt et al.,
2011; Virgen et al., 2007). These proteins are cytidine deaminases
that have canonical deaminase domains (H-x-E-x24−28-P-C-x-x-C)
where the histidine and two cysteines coordinate a zinc cofactor,
with the glutamate serving in proton transfer (MacGinnitie et al.,
1995). The A3 proteins contain either a single cytidine deaminase
domain (A3A, A3C, A3H) or duplicated domains (A3B, A3D, A3F,
and A3G). Following entry of virus containing A3G, this enzyme
causes deamination of cytidine to uridine during minus strand
DNA synthesis, ultimately resulting in G-to-A mutations (Chelico
et al., 2006; Yu et al., 2004).
HIV-1 has evolved a Vif protein to counter incorporation of
select A3 proteins during virus maturation by interacting with and
shunting these proteins to the proteasome via the Cul5/ElonginB/lsevier Inc.
s).C/rbx E3 ubiquitin ligase (Liu et al., 2004; Marin et al., 2003; Mehle
et al., 2004; Sheehy et al., 2003; Yu et al., 2003). Of the A3 proteins,
the double deaminase domain proteins (A3B, A3D, A3F, and A3G)
are most often associated with the restriction of HIVΔvif (Dang
et al., 2007; Doehle et al., 2005; Sheehy et al., 2002; Wiegand et al.,
2004). Human A3C, a single deaminase domain protein, is incor-
porated into both HIV-1 and HIV-1Δvif and is capable of inducing
G-to-A mutations in the viral genome, although not to the same
extent as A3G (Bourara et al., 2007; Kitamura et al., 2010; Langlois
et al., 2005; Smith et al., 2010; Wang et al., 2008). Investigators
have found that alleic differences of hA3H accounts for the ability
of select hA3H proteins to potently inhibit HIV-1Δvif (Harari et al.,
2009; Li et al., 2010; OhAinle et al., 2008; Ooms et al., 2010; Wang
et al., 2011).
Virus restriction experiments on hA3A performed in epithelial
cell lines such as HeLa or 293 cells indicate that hA3A does not
inhibit HIV-1Δvif (Aguiar et al., 2008; Bishop et al., 2004; Goila-
Gaur et al., 2007). However, hA3A can restrict parvoviruses and
LINE-1 elements (Babushok et al., 2007; Bogerd et al., 2006a,
2006b; Brouha et al., 2003; Muckenfuss et al., 2006). Other studies
showed that hA3A can inhibit the replication of adeno-associated
virus type 2 (AAV-2) through a deaminase-independent mechan-
ism, can activate the DNA damage response, cause preferential
degradation of plasmid DNA, and inhibit human T-cell leukemia
virus type 1 (HTLV-I) (Chen et al., 2006; Landry et al., 2011;
Narvaiza et al., 2009; Ooms et al., 2012; Stenglein et al., 2010).
K. Schmitt et al. / Virology 442 (2013) 82–96 83Recently, we showed that rhesus macaques also express an A3A
protein (rhA3A) that restricted vif-deleted SHIV and to a lesser
extent HIV-1Δvif (Schmitt et al., 2011). We showed that a three
amino acid deletion in hA3A was partially responsible for the lack
of restriction. Currently, we do not know whether the differential
ability of rhA3A and hA3A to restrict lentiviruses is a conserved
property of the corresponding Old World monkey (OWM) and
hominid A3A lineages, respectively. Additionally, no information is
available on whether A3A from New World monkeys (NWM),
which are not known have endemic lentiviruses, are capable of
restricting HIV-1 or SIV/SHIV. In this study, we further deﬁne the
amino acid deletions/substitutions necessary to restore the virus
restriction activity of hA3A. We show that the A3A from one NWM
is capable of restricting SHIV. Finally, we present data that one
OWM A3A protein from Colobus guereza can inhibit lentiviral
replication by novel mechanism.Results
The location of the HA-tag does not effect subcellular location
We determined if fusion of the HA-tag to the N-terminus or
C-terminus of rhA3A affected the nucleocytoplasmic localization of
the protein and restriction of SHIV. 293 cells were transfected with
vectors expressing HA-rhA3G, HA-hA3A, hA3A-HA, HA-rhA3A,
rhA3A-HA, and rhA3A-3XHA. At 48 h, cells were starved, radi-
olabeled for 1 h. and used in immunoprecipitation assays using an
antibody against the HA-tag. As shown in Fig. 1, all A3A proteins
were expressed as doublets, which was previously shown to be
due the initiation of translation at an alternative methionine at
position 12 (Theilen et al., 2010). Interestingly, placement of the
HA-tag at the amino terminus of rhA3A (HA-rhA3A) resulted in a
slight shift in the mobility compared to the rhA3A-HA. Previous
studies have shown that hA3G is localized in the cytoplasm while
rhA3A is found in both the cytoplasm and nucleus (Bogerd et al.,
2006a,2006b; Chen et al., 2006; Goila-Gaur et al., 2007;
Muckenfuss et al., 2006; Schmitt et al., 2011). We examined the
intracellular localization of the HA-tagged A3A proteins using
immunoﬂuorescence and confocal microscopy. We found that
HA-rhA3G was observed exclusively in the cytoplasm as pre-
viously reported (Fig. 2) while HA-rhA3A, rhA3A-HA, and rhA3A-
3XHA were detected in both the cytoplasm and nucleus as it
co-localized with a eGFP-tagged nuclear marker (Fig. 2). Thus, any
differences in the retroviral restriction properties of rhA3A pro-
teins could not be explained by the changes in steady-state levels
of the proteins or subcellular localization.50
25
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Fig. 1. Expression of HA-rhA3G, hA3A-HA, HA-rhA3A, rhA3A-HA, and rhA3A-
3XHA. Panel A. 293 cells were transfected with vectors expressing the proteins
listed above. At 48 h, the cells were starved for methionine/cysteine and radi-
olabeled with 35S-methionine/cysteine for 1 h, cells lysed in 1X RIPA buffer and HA
containing proteins immunoprecipitated using an anti-HA serum as described in
the Materials and methods section.Virus restriction of the HA-tagged rhesus and human A3A proteins
We next determined if fusion of the HA-tag to the N- or
C-terminus of rhA3A affected the restriction of SHIV. For virus
restriction assays, 293 cells were transfected with vectors contain-
ing the SHIVΔvif or SHIVKU−2MC4 genomes and vectors expressing
either HA-hA3A, hA3A-HA, HA-rhA3A, rhA3A-HA, rhA3A-3xHA,
untagged rhA3A or vector alone. At 48 h the culture supernatants
were collected and the infectious titers of the released viruses
determined. As shown in Fig. 3, fusion of the HA-tag to the
N-terminus of rhA3A resulted in approximately a 20-fold reduc-
tion in virus infectivity, which was similar to the results with the
untagged rhA3A (Fig. 3). Fusion of a single HA-tag or a 3X HA-tag
to the C-terminus of rhA3A resulted in a reduction of virus
infectivity by 2–5-fold and 1–2-fold, respectively. All experiments
were performed in triplicate and signiﬁcance in the restriction of
infectious SHIVKU−2MC4 or SHIVΔvif was calculated with respect to
the empty vector control using a Student's two-tailed t-test (*). The
reduction in infectivity was found to be signiﬁcant for the HA-
rhA3A and untagged rhA3A but not signiﬁcant for the rhA3A-HA
or rhA3A-3XHA. From these results, we conclude that HA-rhA3A
more closely reﬂects the native rhA3A with respect to restriction
of lentiviruses.
The N-terminal half of the rhA3A contains the necessary determinants
for virus restriction
We previously showed that a 3 amino-acid indel (27SVR29 in
rhA3A) is important for differential lentivirus restriction between
rhA3A and hA3A (Schmitt et al., 2011). To determine the domains
of rhA3A that could completely restore hA3A lentivirus restric-
tion, we constructed a series of chimeric rhesus/human A3A
proteins and evaluated their restriction properties against
SHIVΔvif and HIV-1Δvif (Fig. 4). We analyzed the stability of
these proteins by transfection of 293 cells with vectors expres-
sing each chimeric protein or HA-rhA3A. At 48 h, transfected cells
were radiolabeled for one hour and the HA-tagged A3 proteins
immunoprecipitated with an anti-HA antibody as described in
Fig. 1. Our results indicate that these chimeric proteins were
readily expressed in 293 cells (Fig. 5). However, these chimeric
proteins had divergent activities on SHIV infectivity with the HA-
rh1−100hA3A efﬁciently restricting infectivity of SHIVΔvif and
HIV-1Δvif while the HA-h1−100rhA3A did not restrict SHIVΔvif
or HIVΔvif infectivity (Fig. 6A and B). From these results we
conclude that N-terminal half of the rhA3A had the necessary
amino acid substitutions for restriction of SHIVΔvif and HIV-
1Δvif. We next analyzed chimeric proteins in which amino acids
1–33, 1–50 and 16–50 amino acids of hA3A were replaced with
the analogous region from rhA3A (rh1−33hA3A, rh1−50hA3A, and
rh16−50hA3A, respectively). When analyzed in restriction assays,
rh1−33hA3A, rh1−50hA3A, and rh16−50hA3A all restricted the repli-
cation of SHIVΔvif and HIV-1Δvif (Fig. 6A and B). We further
narrowed the amino acid changes required with another chi-
meric protein in which amino acids 25–33 of rhA3A were
substituted into the same region of hA3A (rh25−33hA3A). Our
analysis revealed that the rh25−33hA3A had a similar virus
restriction proﬁle to rhA3A (Fig. 6A and B). From these studies
we conclude that the six amino acid substitutions in this region
of rhA3A were sufﬁcient to completely restore hA3A restriction
activity against SHIVΔvif and HIV-1Δvif.
We also determined if rh25−33hA3A was incorporated in viral
nucleocapsids. Previous studies have shown that hA3G but not
hA3A was incorporated into viral nucleocapsids (Aguiar et al.,
2008; Goila-Gaur et al., 2007; Schmitt et al., 2011). For these
experiments, 293 cells were co-transfected with plasmids with
either the HIV-1 or HIV-1Δvif genome and plasmids that expressed
A3 Nuclear Overlay
HA-rhA3A
rhA3A-HA
rhA3A-3XHA
HA-rhA3G
Fig. 2. Subcellular localization of HA-rhA3G, HA-rhA3A, rhA3A-HA, and rhA3A-3XHA. 293 cells were transfected with HA-tagged vectors expressing HA-rhA3G, HA-rhA3A,
rhA3A-HA, or rhA3A-3XHA and a vector expressing an eGFP tagged nuclear marker (Clontech). At 48 h, cells were ﬁxed and stained with anti-HA for 1 h, washed and
detected using a horse anti-rabbit-Ig Cy5 antibody. Cells were examined under a Nikon A1 ﬂuorescent microscope and micrographs taken using a 100 objective with a 2
digital zoom using the E2-C1 software package as described in the Materials and Methods.
K. Schmitt et al. / Virology 442 (2013) 82–9684either HA-hA3G, HA-hA3A, or HA-rh25−33hA3A. At 48 h, virus-
containing supernatants were collected and concentrated by
pelleting through 20% sucrose. Concentrated viruses were resus-
pended in 1 ml of PBS and 50% of each were loaded onto a 20–60%
sucrose step gradient and subjected to centrifugation in the
presence of either 1% Triton-X-100 or PBS. Four fractions were
collected with fraction S1 containing the soluble proteins at the
top of the gradient, fraction S2 a buffer of 20% sucrose separating
the soluble proteins from the viral particle and viral nucleocapsids,
fraction S3 the interface of the 20%:60% fractions containing the
viral particles and viral nucleocapsids, and fraction S4 at the
bottom of the 60% fraction. The Env protein was predominantly
in the S3 fraction in the absence of Trition-X-100 but was
predominantly detected in S1 in the presence of Triton-X-100
while the viral capsid protein was predominantly detected in S1
fraction in the presence ofr absence of Triton-X-100 (Fig. 6C–E).
For the A3 proteins, hA3A, hA3G, and rh25−33hA3A partitioned
to fraction S3 in the absence of Triton-X-100 (Fig. 6C–E).
In the presence of Triton-X-100, hA3A was detected in frac-
tion S1 but not in fractions S2-S4 (Fig. 6C). In contrast, hA3G and
rh25−33hA3A could be detected in fractions S2 and S3 in the
presence of Triton-X-100, suggesting that a portion of hA3Gand rh25−33hA3A were incorporated into the viral nucleocapsid
(Fig. 6D and E).
Differential lentivirus restriction by rhA3A and hA3A maps exclusively
to the AC-Loop1 domain
Molecular insights on the differential lentivirus restriction
properties of rhA3A and hA3A may be gained through structural
models. In a previous study, a structural model of hA3A based
on the related C-terminal half of hA3G or hA3G-CD2 (Holden
et al., 2008) was constructed (Bulliard et al., 2011). This study
identiﬁed 11 residues critical for L1 retrotransposition, which
were proposed to form the polynucleotide-accommodating
groove of A3A (Bulliard et al., 2011). These 11 residues are
highlighted in gray in the protein alignment between hA3A and
rhA3A (Fig. 7A). Notably, a structural model of rhA3A is not yet
available. We therefore constructed structural models of rhA3A
and hA3A based on hA3G-CD2 (Holden et al., 2008) using the
interactive SWISS-MODEL program (Fig. 7B and C). As shown in
Fig. 7A and B, the 25DLSVRGRHQ33 residues in rhA3A are
predicted to completely reside within the Active Center-Loop1
(AC-Loop1) region of rhA3A. A space-ﬁlling model suggests that
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Fig. 3. The site of the HA-tag effects restriction of SHIVΔvif virion infectivity by rhA3A. 293 cells were transfected with 0.5 μg of vectors expressing HA-rhA3A, rhA3A-HA,
rhA3A-3xHA, HA-rhA3G or empty vector and 1 μg of wild-type SHIV or SHIVΔvif molecular clones. At 48 h, the culture medium was harvested and virion infectivity
measured by taking the ratio of infectious viral titers on TZM-bl cells. The experiments were performed at least four times and statistical differences with the untagged
rhA3A control were evaluated using a two-tailed Student's t-test, with po0.05 (▲) considered signiﬁcant. Shown is the mean percentage virion infectivity with the empty
plasmid control normalized to 100%.
Fig. 4. Sequence of the chimeric rhA3A/hA3A proteins analyzed in this study. The sequences shown are based on the hA3A sequence. The differences in rhA3A are indicated
below the hA3A sequence and the identity at positions designated with a dash.
K. Schmitt et al. / Virology 442 (2013) 82–96 85the rhA3A amino acids 25–33 are located in a solvent-accessible
area that is adjacent, but not within the proposedpolynucleotide accommodating groove (Fig. 7C). Notably, the
27SVR29 insertion in rhA3A results in a substantial increase in
K. Schmitt et al. / Virology 442 (2013) 82–9686the rhA3A AC-Loop1 molecular surface compared to hA3A
(Fig. 7C). Thus, the AC-Loop1 region of A3A accounts for the
differential lentivirus restriction properties of rhA3A and hA3A.25
15
Fig. 5. The expression of the rhesus/human chimeric A3A proteins. 293 cells were
transfected with vectors expressing either HA-rhA3A, HA-hA3A, HA-h1−100hA3A,
HA-h1−100rhA3A, HA-rh1−50hA3A, HA-rh1−33hA3A, HA-rh16−50hA3A, HA-rh25
−33hA3A or the empty vector. At 48 h, cells were starved for methionine/cysteine
and then labeled for 1 h with 35S-methionine/cysteine. The cells were lysed on ice
in 1X RIPA buffer, the lysates spun in a microfuge to remove the nuclei and the
HA-tagged proteins immunoprecipitated overnight using a polyclonal antibody
against the HA-tag and Protein-A Sepharose beads. The beads were collected and
washed three times with RIPA buffer and boiled in 2X sample reducing buffer. The
proteins were separated using SDS-PAGE, and autoradiography used to visualize
the proteins.
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Fig. 6. The determinants of rhA3A required to restore virus restriction activity of hA3A.
HA-rh1−100A3A, HA-rh1−50A3A, HA-rh1−33A3A, HA-rh16−50A3A, or HA-rh25−33A3A protein
At 48 h, the culture medium was harvested and virion infectivity measured by taking th
least four times. Shown is the mean percentage virion infectivity with the empty plasmi
evaluated using a two-tailed Student's t-test, with po0.05 (▲) considered signiﬁcant. P
proteins. Panel B. Infectivity of HIV-1 and HIV-1Δvif in the presence of the chimeric A3
nucleocapsids. 293 cells were transfected with plasmids containing the viral genome an
At 24 h, the cells were starved and radiolabeled with 35S-methionine/cysteine fo
ultracentrifugation. The virus was analyzed on sucrose step gradients and fractions S1-Comparison of lentivirus restriction by hominid, Old World monkey
and New World monkey A3A proteins
It remains unclear whether the differential lentivirus restric-
tion properties of rhA3A and hA3A are conserved in their respec-
tive OWM and hominid lineages, respectively. In addition, the
lentivirus restriction properties of NWM A3As is unknown. We
therefore evaluated the SHIV/SHIVΔvif and HIV-1/HIV-1Δvif
restriction properties of A3As from additional OWM species,
Chlorocebus aethiops (grivet monkey; agmA3A) and Colobus guer-
eza (mantled guereza; colA3A), a lesser ape, Hylobates lar (com-
mon gibbon; gibA3A), and NWM species, Saimiri sciureus (squirrel
monkey; sqmA3A) and Aotus trivirgatus (Northern owl monkey;
nomA3A).
Alignment of the protein sequences from these different
primate A3As revealed that the 3 amino acid AC-Loop1 indel in
hA3A versus rhA3Awas conserved in gibA3A and agmA3A/colA3A,
respectively (Fig. 8A). Similar to the OWM A3As, the two NWM
A3As have a 3 amino acid AC-Loop1 insertion, as well as a proline
insertion at position 45 and a deletion of two amino acids at
positions 108–109 within the deaminase domain motif (Fig. 8A).
As expected, phylogenetic analyses show that the A3A amino acid
sequences clustered accordingly with their OWM, hominid and
NWM lineages (Fig. 8B). Expression constructs were prepared and
analyzed for expression in 293 cells to examine the stability ofHIV-1
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293 cells were transfected with vectors expressing HA-hA3G, HA-hA3A, HA-rhA3A,
s and 1 mg wild-type HIV-1 or HIV-1Δvif, SHIVKU2−MC4 or SHIVΔvif molecular clones.
e ratio of infectious viral titers on TZM-bl cells. The experiments were performed at
d control normalized to 100%. Statistical differences with the wild-type control were
anel A. Infectivity of SHIVKU−2MC4 and SHIVΔvif in the presence of the chimeric A3A
A proteins. Panel C–D. The incorporation of hA3A, hA3G, and rh25−33hA3A into viral
d plasmids that expressed hA3A (Panel C), hA3G (Panel D), or rh25−33hA3A (Panel E).
r 24 h. The culture medium was harvested, and the virus concentrated using
S4 collected as described in the Materials and methods.
Fig. 7. Structural models of human versus rhesus macaque A3A. (A) Amino acid alignment of hA3A and rhA3A. Residues highlighted in red correspond to differences
between hA3A and rhA3A. Note that there is a 3 amino-acid indel (dashes) in AC-Loop1. Catalytic site residues are highlighted in cyan, while residues in the polynucleotide
groove (Bulliard et al., 2011) were highlighted in gray. Predicted α-helices (cylinders) and β-sheets (arrows) from the homology models are shown. (B) Homology models for
hA3A and rhA3A based on the crystal structure of hA3G-CD2 (Holden et al., 2008). Magenta spheres indicate the position of the Zinc atom. AC-Loop1 is indicated in green.
(C) Space-ﬁlling models. Residues shaded in gray correspond to 11 residues predicted to be in the A3A groove. Residues in green correspond to AC-Loop1, with amino acids
that vary between rhA3A and hA3A in AC-Loop1 highlighted in red.
K. Schmitt et al. / Virology 442 (2013) 82–96 87these A3A proteins. Our results indicate that these proteins were
expressed at comparable levels and had a similar Mr on SDS-PAGE
to rhA3A (Fig. 9). We next analyzed the ability of these A3A
proteins to restrict the replication of SHIVKU−2MC4, SHIVΔvif, HIV-1,
and HIV-1Δvif (Fig. 10A and B). For the NWM A3A proteins, we
found that sqmA3A restricted the replication of SHIVΔvif but
neither sqmA3A nor nomA3A restricted HIV-1 and HIV-1Δvif.
Thus, the case for evolutionary conservation of lentivirus restric-
tion for NWM A3As is inconclusive. Similar to hA3A, the gibbon
A3A (gibA3A) protein did not restrict HIV-1Δvif but in contrast to
hA3A, gibA3A had no signiﬁcant activity SHIVΔvif (Fig. 10A).
Within the OWM lineage, the agmA3A restricted SHIVΔvif and
HIV-1Δvif but not parental SHIVKU−2MC4 or HIV-1. Interestingly, the
colobus A3A protein (colA3A) potently restricted SHIVKU−2MC4,
SHIVΔvif, HIV-1 and HIV-1Δvif (Fig. 10A and B). Thus,
three OWM A3As exhibited greater lentivirus restriction of SHIVΔ-
vif compared to the 2 hominid A3As, suggesting that thedifferential restriction of lentiviruses by A3A proteins are con-
served within the OWM and hominid lineages.
A novel mechanism for lentivirus restriction by colA3A
The potent restriction of wild type and Δvif viruses may be the
inability of SIV and HIV-1 Vif proteins to interact with the colA3A
protein leading to its incorporation and its subsequent effect on
infectivity. However, when we attempted to analyze virus for the
presence of colA3A, we were unable to detect virus in our
preparations. We also examined the intracellular localization of
the colA3A. We found that similar to rhA3A and hA3A, colA3A was
localized in both the cytoplasm and nucleus (data not shown). We
next determined if there was a defect in virus release by transfec-
tion of 293 cells with vectors expressing hA3G, rhA3A, hA3A,
agmA3A, gibA3A, nomA3A, sqmA3A, or colA3A and either the
SHIVKU−2MC4, SHIVΔvif, HIV-1 or HIV-1Δvif genomes. At 48 h, the
Fig. 8. The sequence and phylogenetic relationships of the seven A3A proteins analyzed in these studies. Panel A. The amino acid sequence of the human, lar gibbon, rhesus
macaque, African green monkey, Colobus monkey, squirrel monkey, and northern owl monkey A3A. Panel B. Nearest neighbor joining tree of seven A3A proteins analyzed in
this study. Bootstrap values were obtained from 1000 subreplicates. Species highlighted in black correspond to A3A proteins analyzed in the study.
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K. Schmitt et al. / Virology 442 (2013) 82–96 89culture supernatants were collected and cell lysates prepared to
assess the levels of p27 or p24 expression. The results from ﬁve
separate experiments indicate that the rhA3G, hA3G, rhA3A, hA3A,
agmA3A, gibA3A, sqmA3A, and nomA3A did not signiﬁcantly
restrict the release of p27 or p24 into the culture medium of cells
transfected in the presence of either SHIVKU−2MC4 or HIV-1
(Fig. 11A and B, E and F). However, co-transfection of the vector
expressing colA3A and SHIVKU−2MC4 or SHIVΔvif resulted in o0.1%
of the p27 protein (SHIVKU−2MC4: range of 0 to 1.2 ng/ml; SHIV-
1Δvif: mean of 0.18 ng/ml, range of 0.04–0.42 ng/ml) being
released into the culture medium compared to the other 6 A3A
proteins tested (SHIVKU−2MC4: mean of 158 ng/ml, range of
79–266 ng/ml;; SHIVΔvif: mean of 123 ng/ml, range of 86–195 ng
/ml) (Fig. 11A and B). Similar results were obtained when 293 cells
were co-transfected with the vector expressing colA3A and either
HIV-1 or HIVΔvif (Fig. 11E–H). In the presence of colA3A, HIV-1 and
HIVΔvif released o0.1% p24 (HIV-1: mean of 0.58 ng/ml, range of
0.21 to 0.91 ng/ml; HIV-1Δvif: mean of 0.48 ng/ml, range of 0.18–
0.60 ng/ml) compared to the other A3A proteins (HIV-1: mean of
1110 ng/ml, range of 700–1272 ng/ml; HIV-1Δvif: mean of
2781 ng/ml; range of 1112–4985 ng/ml) (Fig. 11E and F). When
the cell lysates from the same co-transfections were examined for25
15
Fig. 9. The expression of the A3A proteins from the gibbon, Old World and New
World monkeys. 293 cells were transfected with vectors expressing either HA-
rhA3A, HA-gibA3A, HA-agmA3A, HA-colA3A, HA-sqmA3A, or HA-nomA3A. At 48 h,
cells were starved for methionine/cysteine and then labeled for 1 h with 35S-
methionine/cysteine. The radiolabel was then removed washed, and incubated in
cold excess methionine/cysteine for 6 h. The cells were lysed in 1X RIPA buffer, the
lysates spun in a microfuge to remove the nuclei and the HA-tagged proteins
immunoprecipitated overnight using an antibody against the HA-tag and Protein-A
Sepharose beads. The beads were collected and washed three times with RIPA
buffer and boiled in 2X sample reducing buffer. The proteins were separated using
SDS-PAGE, and autoradiography used to visualize the proteins.
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Fig. 10. The A3A proteins from other Old World and New World monkeys also restrict S
either rhA3A, hA3A, rhA3G, gibA3A, sqmA3A, omA3A, agmA3A, or colA3A proteins and 1
the culture mediumwas harvested and virion infectivity measured by taking the ratio of
times. Shown is the mean percentage virion infectivity with the empty plasmid control n
triplicate determinations and statistical differences with the wild-type control were eva
Panel A. Infectivity of SHIVKU−2MC4 and SHIVΔvif in the presence of NWM, OWM, and ho
NWM, OWM, and hominid A3A proteins.p27 or p24 expression, very little capsid protein was detected
compared to the other A3A proteins analyzed (Fig. 11C and D, G
and H). Taken together, there was approximately a 1000-fold
reduction in the amount of SIV p27 or HIV-1 p24 protein
synthesized and released from cells co-transfected with colA3A.
We next determined if colA3A was inhibiting an early step of
replication. 293 cells were ﬁrst transfected with the viral genome
followed by transfection of colA3A 24 h later. The culture medium
and cell lysates were assessed for the presence of p24 antigen at
72 h following transfection of the viral genome. The results
indicate that colA3A still restricted the replication of HIV-1
(Fig. 12). Similar ﬁndings were obtained for SHIVKU−2MC4 (data
not shown). To rule out that these preparations might have a
cryptic DNase activity, plasmids with the colA3A and each of the
four viral genomes were incubated in the transfection solution for
4 h at 37 1C. The plasmids were then run on agarose gels to
determine if there was any signiﬁcant DNA degradation. We
detected neither the degradation the vector expressing colA3A
nor the viral genomes (data not shown). We also determined if
somehow the viral genomes were not being transfected into cells.
Cells were transfected with plasmids with the HIV-1 or SHIVKU2
−MC4 genomes and colA3A. At 12 h post-transfection, DNA was
isolated from cells and analyzed for presence of the viral genome.
Our PCR results also indicated the presence of the two viral
genomes (data not shown).Colobus A3A does not restrict foreign plasmid DNA
A previous study provided data that hA3A was capable of
restricting foreign plasmid DNA (Stenglein et al., 2010). We
determined if colA3A was capable of restricting foreign DNA in
cells. 293 cells were transfected with vectors expressing hA3A,
rhA3A, or colA3A followed by transfection with the pcEGFP
(expressing the enhanced green ﬂuorescent protein, Clontech;
expressed in pcDNA3.1(+)) or empty vector pcDNA3.1(+) 24 h
later. At 24 h, cells were harvested and analyzed for the number
of EGFP expressing cells by ﬂow cytometry. Our results indicate
that at 48 h hA3A caused a decrease in the number of EGFP
positive cells while rhA3A and colA3A did not cause a statistically
signiﬁcant reduction in the number of EGFP positive cells com-
pared to cells co-transfected with pcDNA3.1(+) and EGFP or cellsHIV-1
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HIVΔvif and HIV-1Δvif. 293 cells were transfected with vectors (0.5 mg) expressing
mg wild-type SHIVKU−2MC4, SHIVΔvif, HIV-1 or HIV-1Δvif molecular clones. At 48 h,
infectious viral titers on TZM-bl cells. The experiments were performed at least four
ormalized to 100%. In all panels, error bars correspond to standard deviations from
luated using a two-tailed Student's t-test, with po0.05 (▲) considered signiﬁcant.
minid A3A proteins. Panel B. Infectivity of HIV-1 and HIV-1Δvif in the presence of
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Fig. 11. The colA3A inhibits SHIV and HIV-1 replication by a novel mechanism. Panels A–D. The colA3A restricts the synthesis and release of viral p27. 293 cells were transfected with vectors expressing either rhA3G, hA3A, rhA3A,
gibA3A, agmA3A, colA3A, nomA3A, or sqmA3A and either SHIVKU−2MC4 and SHIVΔvif. At 48 h, the culture mediumwas collected and lysates prepared from cells. The levels of p27 in the medium (Panels A–B) and cell lysates (Panels
C–D) were determined using commercial p27 kits. In all panels, error bars correspond to standard deviations from triplicate determinations and statistical differences with the wild-type control were evaluated using a two-tailed
Student's t-test, with po0.05 (▲) considered signiﬁcant. Panels E–H. The colA3A restricts the synthesis and release of viral p24. 293 cells were transfected with vectors expressing either rhA3G, hA3A, rhA3A, gibA3A, agmA3A,
colA3A, nomA3A or sqmA3A and either HIV-1, or HIV-1Δvif genomes. At 48 h, the culture medium was collected and lysates prepared from cells. The levels of p27 in the medium (Panels E–F) and cell lysates (Panels G–H) were
determined using commercial p24 kits. In all panels, error bars correspond to standard deviations from triplicate determinations and statistical differences with the wild-type control were evaluated using a two-tailed Student's t-
test, with po0.05 (▲) considered signiﬁcant.
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Fig. 12. The colA3A restricts HIV-1 replication if transfected into cells 24 h after the viral genome. 293 cells were transfected with plasmids with either the HIV-1 or HIVΔvif
genomes. At 24 h, cells were washed and transfected with vectors expressing either hA3G, rhA3A, colA3A or pcDNA3.1(+). At 72 h post-transfection, the culture mediumwas
collected and the cell lysates prepare. The levels of p24 in the medium (Panel A) and cell lysates (Panel B) were assessed using commercially available p24 antigen capture
kits. Infectious virus in the culture medium was determined using TZM-bl cell assays.
K. Schmitt et al. / Virology 442 (2013) 82–96 91transfected with EGFP alone (Fig. 13). These results indicate that
colA3A did not restrict foreign DNA (i.e., pcEGFP).Discussion
The human APOBEC3 genes are widely accepted as potent
antiretroviral genes, with the notable exception of human A3A(hA3A). Human A3A lacked activity against HIV-1Δvif but instead
restricted LINE-1 retrotransposons and DNA viruses, suggesting
that the hA3A may have diverged from its ancient antiretroviral
function. To better understand this evolutionary process, we
sought to document the lentivirus restriction properties of addi-
tional primate A3As.
In a previous report, we showed that the rhesus macaque A3A
(rhA3A) potently restricted the replication of Δvif SHIV and HIV-1
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Fig. 13. The colA3A does not cause restriction of foreign DNA. Expression constructs (3 mg) of HA-tagged rhA3A, hA3A and colA3A were ﬁrst transfected into 293 cells for
24 h. At 24 h post-transfection, the 293 cells were re-transfected with a plasmid encoding a CMV-driven eGFP reporter and assayed for reporter expression. The cells were
removed from the plate and ﬁxed. All samples were analyzed by a ﬂow cytometer and the mean ﬂuorescence intensity (MFI) for eGFP positive cells was calculated. The MFI
ratio and percentage of eGFP cells were calculated for each samples and the experiment was run in triplicate. All groups were compared to the pcDNA3.1(+) plus EGFP
control using a Student's t-test with po0.05 considered signiﬁcant.
K. Schmitt et al. / Virology 442 (2013) 82–9692to a greater extent than hA3A (Schmitt et al., 2011). At ﬁrst glance,
our results appear to be discordant from other investigators who
found no activity with rhA3A (Hultquist et al., 2011). However,
there are important differences in the constructs used in the two
studies. In our study, we fused the HA-tag to N-terminus of rhA3A
while in the other study the investigators fused a 3X-HA tag to the
C-terminus rhA3A. Based on our results presented here, it appears
that the site of the HA-tag does inﬂuence the virus restriction
properties of rhA3A, which may explain the discordant results
from the two studies.
The differential restriction properties of hA3A and rhA3A
against lentiviruses was striking, given that these proteins were
81% identical to each other. We therefore performed detailed
chimeric studies and found that the addition of six amino acid
substitutions (from 27SVR29 to 25DLSVR29 and K33Q) into hA3A
increased the HIV-1Δvif restriction activity of hA3A to the same
level as wild-type rhA3A restricted SHIVΔvif. Interestingly, struc-
tural models revealed that the rhA3A amino acids 25 to 33 map
exclusively onto AC-Loop1, resulting in greater AC-Loop1 molecu-
lar surface in rhA3A compared to hA3A. Due to its predicted
solvent-accessibility, this additional molecular surface may be an
important region for protein–protein interactions. Thus, one pos-
sibility for the enhanced restriction activity of rhA3A may be due
to the existence of additional protein–protein interactions that
normally does not occur with hA3A. Recently, Vif was shown to
recruit the transcription factor CBF-β to the ubiqutin ligase com-
plex to enhance the degradation of hA3G but not hA3A (Jäger
et al., 2011; Zhang et al., 2011). It will be of interest to determine if
rh25−33hA3A is capable of interacting with CBF-β.
Since rhA3A can restrict SHIV/SIV to a greater extent than
hA3A, it raised the question of whether A3A from other OWM and
hominids behave similarly. We therefore characterized the anti-
lentiviral properties of A3A from two additional OWM (agmA3A
and colA3A) and one hominid (gibA3A). The results revealed thatthe OWM A3A proteins restricted SHIV Δvif and HIV-1 Δvif to a
greater extent than hominid A3As. These data provide evidence for
evolutionary conservation of hominid (lack) and OWM (potent)
A3A lentivirus restriction. The reason for the loss of lentivirus
restriction properties of the hominid A3A proteins remains open
to speculation. One possibility is that the lack of lentivirus
infection in hominids resulted in the neofunctionalization of A3A
to restrict DNA viruses and/or L1 retrotransposons. While SIV is
endemic in chimpanzees and gorillas in the wild, these SIV strains
do not uniformly infect chimpanzees and gorillas across Africa
(Santiago et al., 2002; van Heuverswyn et al., 2006). In fact, SIVcpz
likely emerged more recently in these species following cross-
species transmission and recombination of Δ strains from OWM
(Bailes et al., 2003).
Another salient result was that the A3A protein from a colobus
monkey restricted not only SHIVΔvif and HIVΔvif but also the
parental viruses expressing intact Vif proteins. This result could be
due to the inability of Vif proteins of SIV (more speciﬁcally,
SIVmac239) and HIV-1 to counteract colA3A. While a sequence
for SIVcol exists, neither an infectious virus nor an infectious
molecular clone has been described. Furthermore, the SIVcol Vif
protein sequence shares little identity to other lentiviruses
(Courgnaud et al., 2001). It will be of interest to determine if the
SIVcol Vif could antagonize colA3A although a recent study shown
that SIVcol Vif was not expressed and hence is probably very
unstable (Compton and Emerman, 2013). Surprisingly, analysis of
cell lysates and culture supernatants from cells co-transfected
with colA3A and SHIV/HIV revealed substantial inhibition of virion
particle release. When we performed a temporal transfection in
which the viral genome was transfected ﬁrst into 293 cells and
24 h later transfected with the vector expressing colA3A, viral
protein biosynthesis (p24) and release was severely reduced.
These results suggest that colA3A may restrict by a unique post-
entry mechanism in the producer cell. Based on the disruption of
K. Schmitt et al. / Virology 442 (2013) 82–96 93p24 biosynthesis, we believe virus assembly is unlikely to be the
target of the colA3A. Additionally, our preliminary studies suggest
that restriction is likely through a deaminase-independent
mechanism (data not shown). While beyond the scope of this
study, colA3A may: (a) prevent integration of the viral genome;
(b) interact with Tat or Rev which could decrease the synthesis of
transcripts and/or export of unspliced and singly spliced to the
cytoplasm; or (c) could interact with the TAR or RRE to decrease
Tat and/or Rev functions.
The unique properties of colA3A contrasted from two other
OWM A3As (agmA3A and rhA3A). Both agmA3A and rhA3A were
incorporated into Vif-deﬁcient lentivirus particles, and did not
possess a post-entry restriction property. Interestingly, colA3A
belongs to a subclade of OWM A3As that include mandrills and
De Brazza monkeys. Further analysis of the A3A proteins from
these monkey species, as well as other members of the Colobus or
Piliocolubus genus should help determine if the post-entry restric-
tion function of A3A is a unique property of this OWM subclade.
In this study, we also evaluated the lentivirus restriction
properties of A3A from NWM, and found that 1 of 2 NWM A3As
(sqmA3A but not nomA3A) restricted SHIVΔvif. This suggested
that the lentivirus restriction property of NWM A3As may not be
conserved. It is generally accepted that the NWM (Intraorder
Platyrrhini) branched from the ancestors of the OWM and great
apes (Intraorder Catarrhini) approximately 35 million years ago
(Schrago and Russo, 2003; Schrago et al., 2007). To date, lenti-
viruses have not been isolated from the NWM, suggesting there
was no selective pressure for the A3A to evolve restriction activity
against lentiviruses. This suggests that the function of NWM
A3A may have been to restrict other retroviruses or other fami-
lies of viruses. One potential candidate would be the human
T-lymphotropic viruses, which are known to be sensitive to
hA3A, hA3B and hA3H haplotype 2 (Ooms et al., 2012). However,
primate T-lymphotropic viruses most likely originated in Africa
and have been isolated from many species of OWM but not from
NWM. Another potential candidate are the foamy viruses, which
are exogenous, persistent, and non-pathogenic retroviruses in the
subfamily Spumaretrovirinae (Switzer et al., 2005). The foamy
viruses (FVs) have been isolated from a broad range of mammals,
humans, non-human primates (both NWM and OWM), horses,
cows, and cats (Hussain et al., 2003; Meiering and Linial, 2001;
Rethwilm, 2005). For example, FVs express the Bet protein, which
antagonizes A3 restriction and may play a role in both particle
release and viral persistence (Alke et al., 2001; Chareza et al., 2012;
Löchelt et al., 2005; Russell et al., 2005; Saib et al., 1995). A
remarkable feature of the foamy viruses (FVs) is that they have the
capacity to cross species barriers and pose a signiﬁcant risk of
interspecies transmission to humans (Heniene et al., 2003; Switzer
et al., 2004). While no disease has been associated with transmis-
sion of FVs to humans, the ease of primate to primate transmission
implies the co-evolution of host restriction factors since viral
disease mechanisms are not sufﬁcient to prevent cross-species
transmission (Kahn et al., 2009; Leendertz et al., 2008). Since
spumaviruses or FVs are promising candidates for the develop-
ment of viral vectors for gene delivery and vaccination, it will be of
interest to determine if NWM and OWM A3A proteins are capable
of restricting the replication of spumaviruses (Rethwilm,et al.,
2007; Schwantes et al., 2003;Trobridge et al., 2009).Materials and methods
Cells, viruses, and plasmids
293 cells were used for transfections of vectors expressing
various APOBEC3 proteins, full-length SHIV or HIV-1 (NL4-3). TheTZM-bl cell line was used as an indicator cell line to measure the
infectivity of viruses (Derdeyn et al., 2000; Wei et al., 2002). Both
cell lines were maintained in Dulbecco's minimal essential med-
ium (DMEM) with 10% fetal bovine serum (R10FBS), 10 mM Hepes
buffer, pH 7.3, and 100 U/ml penicillin and 100 μg/ml streptomycin
and 5 μg gentamicin. The derivation of SHIVKU−2MC4 (a pathogenic
molecular clone; referred to in the text as SHIV) and SHIVΔvif have
been previously described (Liu et al., 1999; Schmitt et al., 2010; ;
2011). A plasmid with the genome of HIV-1 strain NL4-3 (referred
to in the text as HIV-1) was used to construct a Δvif version
(Schmitt et al., 2011; referred to in text as HIV-1Δvif) (pNL4-3; NIH
AIDS Research and Reference Reagent Program). This plasmid was
digested with PﬂM1, phenol: chloroform extracted, and ethanol
precipitated. The 5′-protruding ends were ﬁlled using DNA Poly-
merase I Large Fragment (Klenow; Promega). The resulting Klenow
fragment reaction produced blunt ended fragments that were
puriﬁed and re-ligated. The resulting plasmid was sequenced
and found to contain a deletion in pNL4-3 vif between base pairs
5301 to 5308. Therefore, only the ﬁrst 79 amino acids of pNL4-3
Vif could be expressed. Plasmid pcDNA3.1(+)-HA-rhA3G was
kindly provided by Nathaniel Landau (New York University School
of Medicine). Plasmids expressing HA-rhA3A and HA-hA3A were
constructed in the laboratory as previously described (Schmitt
et al., 2010; 2011). A plasmid expressing pcDNA3.1(+)-HA-hA3G
used in these studies was provided by the NIH AIDS Reference and
Reagent Program. The genes for rhA3A-HA, rhA3A-3XHA, and the
A3A genes from the African green monkey (HA-agmA3A), C.
guereza (HA-colA3A), Northern owl monkey(HA-nomA3A),squirrel
monkey (HA-sqmA3A) and the Lars gibbon (gibA3A) were synthe-
sized by Genscript, subcloned into pcDNA3.1(+) vector as pre-
viously done for rhA3A and hA3A and sequenced to ensure that
the sequences were correct.Chimeric rh/hA3A proteins, Old and New World monkeyA3A proteins
and detection
The chimeric rhesus/human A3A genes used in this study were
synthesized by Genscript. Upon receipt, the sequence of the genes
was veriﬁed followed by subcloning into pcDNA3.1(+) using
standard cloning procedures. The chimeric proteins included (a)
rh100hA3A, rh1−50hA3A, and rh1−33hA3A,, in which the N-terminal
100, 50, 33 amino acids of hA3A were exchanged for the same
amino acids from rhA3A; (b) rh16−50hA3A and rh24−33hA3A,, in
which amino acids 1–50 and 24–33 of hA3A were exchanged for
the same amino acids from rhA3A; and (c) h100rhA3A, in which the
N-terminal 100 amino acids of rhA3A were exchanged for the
same amino acids from hA3A. The additional hominid, Old World
monkey, and New World monkey A3A proteins were synthesized
based on the sequences from Genbank and subcloned into the
pcDNA3.1(+) vectors as we did for chimeric rh/hA3A proteins.
To assess the stability of these clones in the absence of virus,
293 cells were transfected using PEI transfection reagent (Ex-Gen
500; Fermentas) into a 6-well plate. At 48 h post-transfection, the
cells were starved for methionine/cysteine for 2 h, and radiola-
beled with 300 μCi/ml 35S-Translabel (methionine and cysteine,
Perkin-Elmer, Waltham, MA). Cell lysates were prepared by lysing
radiolabeled cells in radioimmunoprecipitation buffer (RIPA:
50 mM Tris–HCl, pH 7.5; 50 mM NaCl; 0.5% deoxycholate; 0.2%
SDS; 10 mM EDTA) on ice, and the nuclei removed by centrifuga-
tion in a microcentrifuge. The proteins were immunoprecipitated
using an anti-HA polyclonal antibody (sc-805; Santa Cruz) and
collected on protein-A Sepharose. The samples resuspended in 2X
sample reducing buffer, boiled, and the HA-containing A3 proteins
analyzed by SDS-PAGE. Proteins were visualized by standard
autoradiographic techniques.
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293 cells were plated onto 13 mm cover slips in a 6 well plate
and transiently co-transfected with vectors expressing HA-rhA3A,
rhA3A-HA, rhA3A-3xHA, or HA-rhA3G, and a vector expressing a
eGFP tagged nuclear localization marker using TurboFect (MBI
Fermentas) according to the manufacturer's instructions. The
cultures were maintained for 48 h and then ﬁxed in 2% parafor-
maldehyde for 10 min, permeabilized in 0.1% Triton X-100, and
washed in twice in 1X PBS (pH 7.4) for 5 min. Cover slips were
then incubated with a rabbit polyclonal anti-HA antibody (HA-
probe, Santa Cruz) for 1 h at ambient temperature in 1X PBS plus
1% BSA. Cover slips were washed twice with 1X PBS for 5 min and
incubated with a Cy-5 conjugated secondary antibody (Abcam) in
1X PBS +1% BSA for 30 min. The cover slips were washed twice in
1X PBS for 5 min and mounted in a glycerol containing mounting
media (Component A: antifade reagent in glycerol/PBS, Invitro-
gen). A Nikon A1 confocal microscope was used to collect 100
images with a 2 digital zoon, using EZ-C1 software. The pinhole
was set to medium for all wavelengths used. Cy5 and eGFP were
excited using 638 and 488 nm diode lasers, respectively, and the
images were collected using a 670 nm ﬁlter for Cy5 and a 525/
25 nm ﬁlter for eGFP.Inhibition of SHIV and HIV-1 infectivity by A3A
SHIV, SHIVΔvif, HIV-1 or HIVΔvif infectious molecular clones
(1 mg) were co-transfected (0.5 mg) with plasmids expressing
rhA3A, hA3A, rhA3G, hA3G, the various rhesus/human chimeric
protein or the various OWM, NWM and hominoid A3A proteins
using Turbofect (Fermentas) in a 12-well plate. All plasmids (viral
and A3) used in the assays are tested for the ability to transfect and
express viral or A3 proteins before it is used in transfection
studies. At 48 h post-transfection, the culture medium was har-
vested and clariﬁed by low speed centrifugation. Equivalent
amounts of p27 were serially diluted using 10-fold dilutions from
101 to 106 and used to inoculate TZM-bl cells. At 48 h post-
inoculation, the media was removed, cells washed with PBS and
the monolayer ﬁxed using 1% formaldehyde-0.2% glutaraldehyde
in PBS. The cells were washed and incubated in a solution for 2 h
at 37 1C containing 4 mM potassium ferrocyanide, 4 mM potas-
sium ferricyanide, 4 mM magnesium chloride, and 0.4 mg X-gal
per ml. The reaction was stopped and the infectious units (IU) per
ml were calculated (Derdeyn et al., 2000; Wei et al., 2002).Production of HIV-1Δvif and SHIVΔvif virions in the presence of A3
proteins
293 cells seeded onto a 12-well tissue culture plate were co-
transfected with 1 μg of HIV-1, HIV-1Δvif, SHIV, or SHIVΔvif
genomes and 0.5 μg of HA-tagged rhA3A, hA3A, or the other
New World and Old World monkey A3A proteins. After 48 h,
supernatants were collected and the cellular debris was removed
by low speed centrifugation. The cells were lysed in 500 μl of 1X
RIPA (50 mM Tris–HCl, pH 7.5, 50 mM NaCl, 0.5% deoxycholate,
0.2% SDS, 10 mM EDTA) and the nuclei removed by high speed
centrifugation. The amount of Gag p24 or p27 present in the
supernatants and cell lysates was measured using a commercially
available p24 and p27 ELISA kit (Zeptometrix). The experiment
was run in triplicate and the differences between the mean
percentages were calculated using a two-tailed Student's t-test
with po0.05 considered signiﬁcant.Analysis of A3 proteins in the nucleoprotein complex
In order to assess the incorporation of A3A proteins in the
nucleoprotein complex (NPC), 293 cells seeded into a 6-well plate
were co-transfected with HIV-1 or HIV-1Δvif (3 μg) proviral
genomes and either HA-hA3G, HA-hA3A, or HA-rhA25−33hA3A
(1.5 μg) using Turbofect (Fermentas). At 24 h post-transfection,
cells were starved for methionine/cysteine for 2 h and radiola-
beled with 300 μCi of 35S-translabel (methionine and cysteine,
Perkin-Elmer, Waltham, MA) for an additional 24 h. The virus-
containing supernatants were harvested, cleared by low speed
centrifugation, and concentrated by pelleting the virus through a
20% sucrose cushion using ultracentrifugation (SW41 rotor,
247,000 g, 1 h, 4 1C). The concentrated viral pellets were resus-
pended in 1X PBS (pH 7.4) and used on sucrose step-gradients
with or without Triton-X-100. The sucrose step gradients were
prepared as follows: 2.0 ml of a 60% sucrose solution (w/v, in 1X
PBS) was placed into the bottom of a SW55Ti ultracentrifuge tube
and overlaid with 2.0 ml of a 20% sucrose solution (w/v, in 1X PBS).
Immediately prior to the addition of concentrated virus stocks, the
step gradients were overlaid with 100 μl of either 1X PBS or 1%
Triton-X-100 in 1X PBS. This procedure minimized the amount of
time the detergent was exposed to the virions. Samples were then
centrifuged in a SW55Ti rotor (Beckman) at 4 1C for 6 h at
247,000 g. Four fractions of 1.0 ml each were collected from the
top of the gradient with fraction 1 containing soluble proteins,
fraction 2 a buffer of 20% sucrose that separates soluble proteins
from the viral particles or viral cores, fraction 3 that includes the
interphase of 20%:60% sucrose where viral particles and viral cores
accumulate, and fraction 4 containing the 60% sucrose fraction.
Gradient fractions were divided in half, diluted to 1 ml with 1
RIPA buffer and subjected to immunoprecipitation assays using an
HA-speciﬁc antibody (sc-805, Santa Cruz) for the A3 proteins or
anti-HIV-1 patient serum for the capsid and matrix proteins.
Foreign DNA restriction by A3A
293 cells were seeded into 6-well tissue culture plates 24 h
prior to transfection. Cells were ﬁrst transfected with 3 μg of
vectors expressing either HA-rhA3A, HA-hA3A, HA-colA3A, or
pcDNA3.1(+) vector using a polyethylenimine transfection reagent
(ExGen™ 500, MBI Fermentas) according to the manufacturer's
instructions. After 24 h, the cells were re-transfected with 3 μg of a
vector expressing eGFP. Cells were incubated at 371C in 5% CO2
atmosphere for 24 h. The cells were removed from the plate using
Ca2+/Mg2+−free PBS containing 10 mM EDTA. Cells were then ﬁxed
in 2% paraformaldehyde, for 5 min. The cells were washed twice in
1X PBS plus and analyzed using an LSRII ﬂow cytometer. The mean
ﬂuorescence intensity (MFI) for eGFP positive cells was calculated.
The MFI ratio and percentage of eGFP positive cells was calculated
for each sample. Normalized ratios from six separate experiments
were averaged and the standard error calculated. All groups were
compared to pcDNA3.1(+) plus eGFP control using a Student's t-
test with po0.05 considered signiﬁcant.References
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